Zaveg 10 mg/spray belongs to the generic category of Zavegepant. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Zaveg 10 mg/spray. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Zavegepant and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

*Up to 10% Discount
(Depends on pharmacy)
/ Piece
Zaveg 10 mg/spray may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Zaveg 10 mg/spray is provided below to help users gain a clear understanding of this medicine.
Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. The relationship between pharmacodynamic activity and the mechanism by which zavegepant exerts its clinical effects is unknown. No clinically relevant differences in resting blood pressure were observed when zavegepant was concomitantly administered with sumatriptan (12 mg subcutaneous, given as two 6 mg doses separated by one hour) compared with sumatriptan alone to healthy volunteers.
The recommended dose of Zavegepant is 10 mg given as a single spray in one nostril, as needed. The maximum dose that may be given in a 24-hour period is 10 mg (one spray). The safety of treating more than 8 migraines in a 30-day period has not been established.
Avoid use with drugs that inhibit OATP1B3 or NTCP transporters.
Avoid use with drugs that induce OATP1B3 or NTCP transporters.
Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after Zavegepant administration.
Most common adverse reactions (at least 2% of patients treated with Zavegepant and greater than placebo) were taste disorders, nausea, nasal discomfort, and vomiting.
Pregnancy: There are no adequate data on the developmental risk associated with the use of Zavegepant in pregnant women. No adverse developmental effects were observed following subcutaneous administration of zavegepant to pregnant animals at doses associated with plasma exposures higher than those used clinically. Lactation: There are no data on the presence of zavegepant or its metabolites in human milk, the effects of zavegepant on the breastfed infant, or the effects of zavegepant on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Zavegepant and any potential adverse effects on the breastfed infant from Zavegepant or from the underlying maternal condition.
Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity Reactions including facial swelling and urticaria have occurred with ZAVZPRET.Hypertension: New-onset or worsening of pre-existing hypertension may occur.Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Other drugs for migraine
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Source: Data source of Indications and Usages, Pharmacology, Dosage & Administration, Drug Interactions, Side Effects, Use during Pregnancy & Lactation, Precautions & Warnings, Use in Special Populations, Therapeutic Class, and Storage Conditions is the concerned medicine company or respective organization.
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

N:B-All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines"
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023